Patent application number | Description | Published |
20080261308 | DRY POWDER CELL CULTURE PRODUCTS AND METHODS OF PRODUCTION THEREOF - The present invention relates to nutritive medium, medium supplement, media subgroup and buffer formulations. The present invention provides powder nutritive medium, medium supplement and medium subgroup formulations, e.g., cell culture medium supplements (including powdered sera such as powdered fetal bovine serum (FBS)), medium subgroup formulations and cell culture media comprising all of the necessary nutritive factors that facilitate the in vitro cultivation of cells. The invention further provides powder buffer formulations that produce particular ionic and pH conditions upon reconstitution with a solvent. The invention provides methods for production of media, media supplement, media subgroup and buffer formulations, and also provides kits and methods for cultivation of prokaryotic and eukaryotic cells, particularly bacterial cells, yeast cells, plant cells and animal cells (including human cells) using these dry powder nutritive media, media supplement, media subgroup and buffer formulations. | 10-23-2008 |
20080311660 | Dry powder cell culture products and methods of production thereof - The present invention relates to nutritive medium, medium supplement, media subgroup and buffer formulations. The present invention provides powder nutritive medium, medium supplement and medium subgroup formulations, e.g., cell culture medium supplements (including powdered sera such as powdered fetal bovine serum (FBS)), medium subgroup formulations and cell culture media comprising all of the necessary nutritive factors that facilitate the in vitro cultivation of cells. The invention further provides powder buffer formulations that produce particular ionic and pH conditions upon reconstitution with a solvent. The invention provides methods for production of media, media supplement, media subgroup and buffer formulations, and also provides kits and methods for cultivation of prokaryotic and eukaryotic cells, particularly bacterial cells, yeast cells, plant cells and animal cells (including human cells) using these dry powder nutritive media, media supplement, media subgroup and buffer formulations. | 12-18-2008 |
20090028838 | HEMATOPOIETIC CELL CULTURE NUTRIENT SUPPLEMENT - The present invention provides a serum-free supplement which supports the growth of hematopoietic cells in culture. Also provided are a medium comprising a basal medium supplemented with the serum-free supplement of the present invention. The present invention also provides methods for culturing and for differentiating hematopoietic cells. | 01-29-2009 |
20100297090 | HEMATOPOIETIC CELL CULTURE NUTRIENT SUPPLEMENT - The present invention provides a serum-free supplement which supports the growth of hematopoietic cells in culture. Also provided are a medium comprising a basal medium supplemented with the serum-free supplement of the present invention. The present invention also provides methods for culturing and for differentiating hematopoietic cells. | 11-25-2010 |
20110129926 | DRY POWDER CELL CULTURE PRODUCTS AND METHODS OF PRODUCTION THEREOF - The present invention relates to nutritive medium, medium supplement, media subgroup and buffer formulations. The present invention provides powder nutritive medium, medium supplement and medium subgroup formulations, e.g., cell culture medium supplements (including powdered sera such as powdered fetal bovine serum (FBS)), medium subgroup formulations and cell culture media comprising all of the necessary nutritive factors that facilitate the in vitro cultivation of cells. The invention further provides powder buffer formulations that produce particular ionic and pH conditions upon reconstitution with a solvent. The invention provides methods for production of media, media supplement, media subgroup and buffer formulations, and also provides kits and methods for cultivation of prokaryotic and eukaryotic cells, particularly bacterial cells, yeast cells, plant cells and animal cells (including human cells) using these dry powder nutritive media, media supplement, media subgroup and buffer formulations. | 06-02-2011 |
20130109094 | Dry powder cell culture products and methods of production thereof | 05-02-2013 |
Patent application number | Description | Published |
20080299168 | Stabilized Polymeric Delivery System - The invention relates to a delivery system for the sustained and controlled delivery of a group of bioactive agents. More particularly, the invention relates to a delivery system and a method for delivery of a bioactive agent containing a nucleophilic functional group by means of a biodegradable, sustained-release implant. The implant may be a preformed implant, microparticles or an in situ formed implant. The implant includes a biodegradable thermoplastic polymer, the bioactive agent having a nucleophilic group substituent and a stabilizing associate as well as other optional components. The combination of the stabilizing associate with the bioactive agent prevents and/or minimizes and/or lessens degradation of the thermoplastic polymer by the bioactive agent. | 12-04-2008 |
20090092650 | Sustained Delivery Formulations of Octreotide Compounds - The present invention relates to an octreotide sustained release delivery system for treatment of diseases relating to somatotropin and/or somatostatin. The sustained release delivery system of the invention includes a flowable composition containing an octreotide compound, and an implant containing the octreotide compound. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid and an octreotide compound. | 04-09-2009 |
20090325879 | CONTROLLED RELEASE COPOLYMER FORMULATION WITH IMPROVED RELEASE KINETICS - The present invention provides a constant release copolymer composition adapted for use in a controlled release formulation for a bioactive agent, such as a formulation adapted for implantation within a patient's body tissues as a depot to release the agent over a period of time, wherein the copolymer provides a substantially constant rate of release of the bioactive agent over the time period for which the depot persists in the body tissues. The copolymer includes a PLG copolymer and a PLG oligomer of about 5-10 kDa average molecular weight, which can lack free carboxylic acid groups. When the PLG copolymer is a low burst copolymer, the constant release copolymer composition is a low burst, constant release copolymer composition adapted for implantation in the body tissues of a mammal, wherein a substantially constant rate of release of the bioactive agent is achieved. | 12-31-2009 |
20100266655 | SUSTAINED DELIVERY FORMULATIONS OF RISPERIDONE COMPOUNDS - The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite, or a prodrug thereof. | 10-21-2010 |
20100292195 | LOW BURST POLYMERS AND METHODS TO PRODUCE POLYMER - A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced “initial burst” effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use. | 11-18-2010 |
20110171305 | DEHYDRATED HYDROGEL INCLUSION COMPLEX OF A BIOACTIVE AGENT WITH FLOWABLE DRUG DELIVERY SYSTEM - The invention provides a controlled release biodegradable polymer formulation adapted for administering bioactive agents such as therapeutic proteins to a patient through implantation of a bolus that forms a depot within the patient's body tissues. The formulation includes a dehydrated inclusion complex of the bioactive agent within a hydrogel, wherein the hydrogel can comprise a polymerized polyalkyleneglycolyl diacrylate, and, optionally, polyalkyleneglycolyl monoacrylates, including methacrylates. Alternatively, the hydrogel can comprise hyaluronic acid, chitosan, agarose, polyvinylacetate, polyvinylpyrrolide, or polyvinylalcohol nanoparticles. The bioactive agent can be a macromolecular material, such as a protein. A method of forming the inventive formulation is also provided, as well as a method for using the formulation in the treatment of a malcondition in a patient in need thereof. | 07-14-2011 |
20120301535 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME - Nanoparticles having a core and a corona of ligands covalently linked to the core, wherein differing species of peptides are bound to the nanoparticles and incorporated into various dosage forms. | 11-29-2012 |
20130045271 | STEROID HORMONE DELIVERY SYSTEMS AND METHODS OF PREPARING THE SAME - The present invention is directed to steroid hormone delivery systems and methods of preparing the same. In particular, the steroid hormone delivery systems provided include a primary construct having one or more hydrophobic steroid hormone esters in the form of a liposome, a lipid particle, a micelle, an emulsion or a niosome which is then formulated into a secondary construct for administration. Exemplary secondary constructs include a film for sublingual or buccal administration. | 02-21-2013 |
20140017299 | STEROID HORMONE DELIVERY SYSTEMS AND METHODS OF PREPARING THE SAME - The present invention is directed to film dosage compositions for delivery of testosterone esters. In particular, a film dosage composition is provided that includes: a) a first region including: i) a first polymeric matrix and ii) a first plurality of particles including: 1) a first testosterone ester and 2) a first surfactant; and b) a second region including: i) a second polymeric matrix and ii) a second plurality of particles including: 1) a second testosterone ester and 2) a second surfactant. | 01-16-2014 |
20140073678 | ANTI-PAIN AND ANTI-NAUSEA AND/OR VOMITING COMBINATORIAL COMPOSITIONS - In one aspect, the present invention discloses combinational compositions for treating users experiencing symptoms associated with a migraine or other central nervous system related pain disorder that can cause or exacerbate nausea and/or vomiting or other central nervous system related pain disorder that can cause or exacerbate nausea and/or vomiting. The combinational composition includes a first pharmaceutical active component for treating pain, and a second pharmaceutical active component for treating nausea and/or vomiting and/or vomiting in a user. | 03-13-2014 |
20140094484 | SUSTAINED DELIVERY FORMULATIONS OF RAPAMYCIN COMPOUNDS - The present invention relates to a rapamycin sustained release delivery system for treatment of diseases responsive to rapamycin. The sustained release delivery system of the invention includes a flowable composition containing rapamycin or a rapamycin derivative, which is capable of providing an implant containing the rapamycin or derivative thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid and rapamycin or a rapamycin derivative. | 04-03-2014 |
20140255473 | STEROID HORMONE DELIVERY SYSTEMS AND METHODS OF PREPARING THE SAME - The present invention is directed to steroid hormone delivery systems and methods of preparing the same. In particular, the steroid hormone delivery systems provided include a primary construct having one or more hydrophobic steroid hormone esters in the form of a liposome, a lipid particle, a micelle, an emulsion or a niosome which is then formulated into a secondary construct for administration. Exemplary secondary constructs include a film for sublingual or buccal administration. | 09-11-2014 |
20140261990 | MULTI-LAYER FILMS HAVING UNIFORM CONTENT - The present invention relates to a method of forming a multi-layered film product, including the steps of forming a single-layered film having a length and a width and folding said single-layered film over on itself along said length at least once to form a multi-layered film having at least 2 layers in a face-to-face engagement. The single-layered film includes at least 2 lanes in a side-by-side arrangement along the length of the single layered film, wherein: a) each of said lanes spans the length of said single-layered film; b) each of said lanes spans at least a portion of the width of said single-layered film; c) said lanes that are adjacent to one another meet at a fold line that runs parallel to the length of said single-layered film; and d) at least one of said at least 2 lanes comprises at least one active component. | 09-18-2014 |
20140271787 | CONTINUOUS SINGLE LAYER FILM STRUCTURE INCLUDING DISCRETE DOMAINS - Disclosed herein is a soft, flexible, continuous, single-layer structural directional active delivery device such as a film product with discrete domains useful for controlled administration of the active to a patient. The discrete domains are substantially inseparable from one another, have different rates of dissolution and advantageously offer superior adhesion to the body of the patient while administering the active directionally and effectively. | 09-18-2014 |
20140271788 | SUBLINGUAL AND BUCCAL FILM COMPOSITIONS - The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent. | 09-18-2014 |
20140271789 | SUBLINGUAL AND BUCCAL FILM COMPOSITIONS - The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent. | 09-18-2014 |
20140275194 | FILMS AND DRUG DELIVERY SYSTEMS FOR RIZATRIPTAN - The invention relates to film products including a polymer component and a therapeutically effective amount of rizatriptan or a pharmaceutically acceptable salt thereof. The invention further relates to film products including a polymer component and a therapeutically effective amount of rizatriptan benzoate. | 09-18-2014 |